Finance

Lists
Outlook: 73.7% bullish·10.5% bearish
Go to analysis
PCRX:NASDAQ
Pacira Biosciences Inc
$36.32
-0.21%
(-0.075) 1D
Oct 9, 3:02:12 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PCRX...
Open
$36.33
High
$36.36
Low
$36.31
Mkt. cap
1.45B
Avg. vol.
1.50M
Volume
3.76M
P/E ratio
104.65
52-wk high
$36.40
52-wk low
$18.80
EPS
$0.35
Beta
0.25
Shares outstanding
39.86M
No. of employees
827
Open
$36.33
High
$36.36
Low
$36.31
Mkt. cap
1.45B
Avg. vol.
1.50M
Volume
3.76M
P/E ratio
104.65
52-wk high
$36.40
52-wk low
$18.80
EPS
$0.35
Beta
0.25
Shares outstanding
39.86M
No. of employees
827
News stories
From web sources and news partners
About Pacira Biosciences Inc
CEO-
Employees827
Founded2006
HeadquartersBrisbane, California, United States
SectorPharmaceutical industry
Websitepacira.com
Analyst ratings
Based on 9 analysts giving stock ratings to PCRX in the past 3 months
Hold
Buy
0
Hold
8
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for PCRX in the last 3 months.
Highest
Current $36.32
$36.50 (+0.51%)
Average
$32.86 (-9.51%)
Lowest
$23.00 (-36.67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Hold
Reiterated
$36.50
+0.5%
10/09/2026
Douglas Miehm
RBC Capital
Hold
Reiterated
$36.50
+0.5%
10/08/2026
Douglas Tsao
H.C. Wainwright
Hold
Downgraded
$36.50
+0.5%
10/09/2026
Les Sulewski
Oppenheimer
Hold
Downgraded
-
-
10/08/2026
Dennis Ding
Jefferies
Hold
Downgraded
$36.00
-0.9%
10/08/2026
Serge Belanger
Needham
Hold
Downgraded
-
-
10/08/2026
Anish Nikhanj
Truist Financial
Hold
Downgraded
$36.50
+0.5%
10/09/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
$32.00
-11.9%
09/23/2026
Gregory Renza
Truist Financial
Buy
Initiated
$30.00
-17.4%
08/17/2026
Jenna Davidner
Barclays
Hold
Maintained
$25.00
-31.2%
08/17/2026
Hardik Parikh
J.P. Morgan
Sell
Maintained
$23.00
-36.7%
08/10/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
$0.73 / $0.65
+12.79%beat
Revenue / Est. (USD)
192.40M / 191.00M
+0.73%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
179.52M
196.87M
177.38M
192.40M
Cost of goods sold
34.28M
45.80M
36.41M
44.16M
Cost of revenue
34.28M
45.80M
36.41M
44.16M
Research and development expenses
25.97M
37.45M
28.07M
30.24M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
91.80M
101.61M
93.94M
91.81M
Operating expense
132.08M
153.38M
136.34M
136.37M
Total operating expenses
166.36M
199.18M
172.75M
180.54M
Operating income
13.15M
-2.31M
4.62M
11.86M
Other non operating income
-110.00K
-134.00K
-135.00K
-34.00K
EBT including unusual items
9.52M
571.00K
5.00M
2.56M
EBT excluding unusual items
17.30M
-4.04M
2.72M
10.15M
Income tax expense
4.09M
-1.07M
2.08M
-2.10M
Effective tax rate
42.97%
-186.69%
41.66%
-82.11%
Other operating expenses
-
-
-
-
Net income
5.43M
1.64M
2.92M
4.65M
Net profit margin
3.03%
0.83%
1.64%
2.42%
Earnings per share
0.70
0.57
0.60
0.73
Interest and investment income
8.53M
2.30M
1.93M
1.94M
Interest expense
-4.28M
-3.89M
-3.70M
-3.62M
Net interest expenses
4.26M
-1.60M
-1.77M
-1.68M
Depreciation and amortization charges
-
-
-
-
EBITDA
28.84M
24.53M
25.96M
33.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps